Waddell & Reed Financial Inc. increased its holdings in shares of Allergan plc (NYSE:AGN) by 7.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 75,000 shares of the company’s stock after acquiring an additional 5,000 shares during the quarter. Waddell & Reed Financial Inc.’s holdings in Allergan were worth $12,504,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Flagship Harbor Advisors LLC acquired a new position in shares of Allergan in the 2nd quarter worth approximately $129,000. Kaizen Advisory LLC increased its stake in Allergan by 156.2% during the 2nd quarter. Kaizen Advisory LLC now owns 830 shares of the company’s stock worth $138,000 after buying an additional 506 shares during the period. Migdal Insurance & Financial Holdings Ltd. increased its stake in Allergan by 3,193.3% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 988 shares of the company’s stock worth $165,000 after buying an additional 958 shares during the period. Avestar Capital LLC increased its stake in Allergan by 46.1% during the 1st quarter. Avestar Capital LLC now owns 1,185 shares of the company’s stock worth $183,000 after buying an additional 374 shares during the period. Finally, Aries Wealth Management purchased a new stake in Allergan during the 2nd quarter worth approximately $202,000. Institutional investors own 77.38% of the company’s stock.
AGN has been the topic of several recent research reports. Zacks Investment Research raised shares of Allergan from a “hold” rating to a “buy” rating and set a $189.00 price objective on the stock in a research report on Monday, July 2nd. Argus reissued a “hold” rating on shares of Allergan in a research report on Thursday, July 5th. Mizuho reissued a “neutral” rating and issued a $194.00 price objective on shares of Allergan in a research report on Monday, July 9th. Credit Suisse Group set a $213.00 price objective on shares of Allergan and gave the company a “buy” rating in a research report on Friday, July 13th. Finally, Wells Fargo & Co set a $240.00 target price on shares of Allergan and gave the company a “buy” rating in a research report on Thursday, July 19th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and eighteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $211.91.
In other news, Director Joseph H. Boccuzi purchased 900 shares of the stock in a transaction dated Thursday, August 30th. The stock was acquired at an average cost of $190.59 per share, for a total transaction of $171,531.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Christopher J. Coughlin purchased 10,000 shares of the stock in a transaction dated Thursday, September 6th. The shares were purchased at an average price of $190.64 per share, with a total value of $1,906,400.00. The disclosure for this purchase can be found here. Company insiders own 0.37% of the company’s stock.
NYSE:AGN traded up $1.06 during trading hours on Friday, reaching $183.28. 2,084,762 shares of the company’s stock were exchanged, compared to its average volume of 2,552,896. Allergan plc has a 1-year low of $142.81 and a 1-year high of $207.24. The stock has a market cap of $64.66 billion, a P/E ratio of 11.21, a P/E/G ratio of 1.47 and a beta of 1.19. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.00 and a quick ratio of 0.85.
Allergan (NYSE:AGN) last released its earnings results on Thursday, July 26th. The company reported $4.42 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.13 by $0.29. The company had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $3.92 billion. Allergan had a negative net margin of 10.29% and a positive return on equity of 8.60%. The business’s revenue was up 2.3% on a year-over-year basis. During the same quarter last year, the business earned $4.02 EPS. Sell-side analysts expect that Allergan plc will post 16.29 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Monday, September 17th. Stockholders of record on Friday, August 17th were issued a $0.72 dividend. The ex-dividend date of this dividend was Thursday, August 16th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.57%. Allergan’s dividend payout ratio is presently 17.61%.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.
Further Reading: What is the NASDAQ?
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.